2. Introduction
âȘ Helicobacter pylori (H. pylori) remains one of the most common
worldwide human infections and
âȘ It is associated with a number of important upper
gastrointestinal (GI) conditions
â including chronic gastritis,
â peptic ulcer disease,
â gastric malignancy.
1/8/2014
2
3. Epidemiology
âȘ Almost 50% of worlds population is affected by
H.pylori
âȘ Genetic studies shows that humans are infected
for more than 58000 years at time they migrated
from Africa
1/8/2014
3
4. Time of acquisition of
infection
In developing nations
The majority of
children's are
infected before
the age of 10
years
And almost
reaching 80%
in adults
reaching the
age of 50
years
1/8/2014
4
5. In united states..
Unusual
before the
age of 10
years
Reaches
10% in
adults in the
age between
18 â 30 years
Reaches
almost 50%
in those
older than
60 years
1/8/2014
5
6. Risk factors
1. Socioeconomic status
âą
âą
âą
âą
âą
Density of housing
Over crowding
Number of siblings
Sharing the same bed
Lack of running water
2. Consumption of salted food- increases
persistence of infections and also predisposes to
risk of gastric cancer
1/8/2014
6
7. Hereditary and genetic
factors
âȘ Hispanics and African-Americans have a higher
rate of infection than Caucasians.
âȘ Monozygotic twins raised in different households
have a greater concordance of H. pylori infection
than do dizygotic twins raised apart
1/8/2014
7
8. Routes of transmission
âȘ Humans are the major reservoir of the H.pylori
âȘ Person to person transmission in the form of
1.
2.
3.
Fecal â oral
Oral â oral
Gastric â oral
1/8/2014
8
9. Risks of transmission
âȘ Childrens who consume untreated stream
water, uncooked vegetables
âȘ Exposure to diarrheal stools, vomitus of the
infected persons
âȘ Dentists and oral hygienists who have exposures to
dental plaques and saliva
âȘ Iatrogenic infection in the form of contaminated
endoscopes and other gastric devices
1/8/2014
9
10. Microbiology
âȘ Morphology:
âą H. pylori is a spiral shaped,
âą microaerophilic, gram negative bacterium
âą measuring approximately 3.5 microns in length and 0.5
microns in width
âą It has multiple unipolar flagella and it is actively motile
âą biochemically characterized as catalyse, oxidise, and
urease positive.
1/8/2014
10
11. Growth and culture characters
âȘ Growth and culture characters
âą Itâs a slow growing organism
âą can be cultured on blood agar
âą selective media is Skirrow's media (with
vancomycin, polymyxin B, and trimethoprim, chocolate
medium) incubated at 37ÂșC in a 5 percent oxygen
atmosphere for three to seven days
âą The colonies are translucent and 1â2 mm in diameter.
1/8/2014
11
15. Diagnosis â when to test
ACG recommendations
âȘ Testing for H. pylori should be performed only if
the clinician plans to offer treatment for positive
results
âȘ Testing is indicated in patients with gastric MALT
lymphoma, active peptic ulcer disease, or a past
history of documented peptic ulcer
1/8/2014
15
16. Diagnosis â when to test
âȘ patients with
uninvestigated
dyspepsia who are
under the age of 55
years and have no
alarm features
alarm features
âȘ Deciding which test to use
in which situation relies
heavily upon whether a
patient requires evaluation
with upper endoscopy and
the strengths, weaknesses,
and costs of the individual
tests
âȘ unexplained weight loss,
âȘ bleeding,
âȘ anaemia,
âȘ early satiety,
âȘ Progressive
âȘ dysphagia, odynophagia,
âȘ recurrent vomiting,
âȘ family history of GI
cancer, previous
esophagogastric
malignancy
1/8/2014
16
17. Supported by the evidence
Controversial
Indications for testing and
treatment of H.pylori infection
Active peptic ulcer disease (gastric or
Functional dyspepsia
duodenal ulcer)
âȘ
Confirmed history of peptic ulcer
âȘ
âȘ
Gastric MALT-lymphoma (low grade)
âȘ Unexplained iron deficiency anaemia
GERD
Persons using NSAIDs or before
starting NSAIDs
or ITP
Following endoscopic resection of early
gastric cancer
âȘ Populations at higher risk of gastric
cancer
âȘ
Uninvestigated dyspepsia (if H. pylori
population prevalence high)
1/8/2014
17
18. Types of diagnostic test
Non endoscopic tests
Endoscopic tests
1. Serology
(quantitative or
qualitative IgG)
1. Histology
2. Urea breath test (13C
or 14C)
3. Culture
3. Stool antigen test
2. Rapid urease test
4. Polymerase chain
reaction assay
1/8/2014
18
19. Serology
âȘ ELISA technology to detect IgG antibodies is
inexpensive, non-invasive.
âȘ high sensitivity (90 to 100%), variable specificity
(76 to 96%) & accuracy( 83 to 98%).
âȘ It needs confirmation with another method such
as a stool antigen or urea breath test before
starting treatment
âȘ The âserological scarâ may be present even after
successful eradication of organism
1/8/2014
19
20. Urea breath test (UBT)
âȘ detects active H. pylori infection, confirming the
accuracy of serology and documenting successful
treatment.
âȘ The specificity is more than 95%, sensitivity of the test
is 88% to 95%
âȘ false-negative results reported in patients taking
antisecretory therapy such as PPIs,bismuth, or
antibiotics.
âȘ antibiotics should be stopped at least four weeks and
PPIs at least one week before breath testing.
âȘ UBT is not accurate in patients who have had gastric
respective surgery.
1/8/2014
20
22. Stool antigen assay
âȘ It is an immunoassay to detect the presence of
h.pylori antigen in stools
âȘ The sensitivity and specificity are 94% and
97%, respectively
âȘ sensitivity of stool testing is negatively affected by
PPIs, bismuth, and antibiotics which affects the
bacterial load
âȘ Its used both for diagnosis and confirm the
eradication .
1/8/2014
22
23. Endoscopic tests â biopsy
urease testing
Tissue from the antral biopsy is
placed in agar well containing
urea and pH reagent
The urease cleaves the urea to
liberate ammonia
This process changes the
medium alkaline and produces a
color change
1/8/2014
23
24. Biopsy urease testing
âȘ commercially available kits include
CLOtest, PyloriTek, and Hp-fast
âȘ The CLOtest may become positive as early as one
hour after collection, but a final reading at 24 hours
is recommended
âȘ The sensitivity is 90 to 95% & specificity is 95 to
100%
âȘ false positive tests are unusual. False negative
results occur in recent gastrointestinal bleeding or
with the use of PPIs, H2
antagonists, antibiotics, or bismuth-containing
compounds
1/8/2014
24
25. Rapid urease testing
âȘ To know patient's H. pylori status before discharge
from the endoscopy suite.
âȘ biopsy specimens are sandwiched between a
reagent strip with a pH indicator and a pad
containing urea.
âȘ One hour sensitivity is 89 to 98 percent and
specificity is 89 to 93 percent.
1/8/2014
25
27. Histology
âȘ In addition to make diagnosis of H.pylori the biopsy and
histology also reveals intestinal metaplasia, MALT
omas, dysplasia and neoplasia
âȘ In addition to biopsying âclinically suspiciousâ
areas, taking multiple biopsies and sampling lesser and
greater curvatures of gastric antrum and body are
important.
âȘ It is gold standard for identifying infection, with
reported sensitivity and specificity as high as 95% and
98%
âȘ LimitationsâŠ
âȘ Brush cytologyâŠ.
1/8/2014
27
29. A silver stain (Warthin Starry) of H.pylori
on gastric mucus-secreting epithelial cells
(x1000).
This picture is notorious because it is of
Dr. Marshall's stomach biopsy taken 8
days after he drank a culture of H. pylori.
1/8/2014
29
30. Culture
âȘ Its fastidious and difficult to culture and require
special culture media
âȘ Culture is indicated when treating cases not
responding to treatment and suspected antibiotic
resistance
âȘ Even though the in vitro sensitivity will not
guarantee the treatment results
1/8/2014
30
31. This is a 3 day culture of
H.pylori on blood agar
1/8/2014
31
33. Triple therapy
âȘ Itâs the most commonly
recommended therapy
âȘ The duration of therapy must
be 14 days and all drugs in
BD dose
âȘ The cure rate is >80%
âȘ Metronidazole 500mg can be
substituted for amoxy in
penicillin allergic patients
1/8/2014
33
34. Quadruple therapy
âȘ Dose : 4 times a day
âȘ Duration : 14 days
âȘ appropriate as initial
therapy in areas in which the
prevalence of resistance
to clarithromycin or
metronidazole is >20%
âȘ in patients with recent or
repeated exposure to
clarithromycin or
metronidazole
Eradication rate 70 â 85%
1/8/2014
34
35. Sequential regimen
Regimen
Days
(PPI + Amoxy 1000 mg) BD 5 + 5
followed by
(PPI+ Clarithromycin 500
mg + Tinidazole 500 mg) BD
Eradication
rate
90%
âą It has overall eradication rate better than triple
therapy 90% vs 80%
âąParticularly superior if bacteria is clarithromycin
resistant ( 89% Vs 29%)
1/8/2014
35
36. Eradication confirmation
âȘ Eradication may be confirmed by a urea breath test, fecal
antigen test, or upper endoscopy performed four weeks or
more after completion of therapy.
âȘ Its indicated in following situations
1.
2.
3.
4.
Patients who have persistent symptoms after H. pylori treatment
for dyspepsia
Patients who had an H. pylori associated ulcer
Patients who had gastric mucosa associated lymphoid tissue
(MALT) lymphoma
Patients who had resection for early gastric cancer.
1/8/2014
36
37. Treatment failures and
persisitance of H.pylori
âȘ The initial treatment results in 25% failures
âȘ The reasons for failure are
1.
2.
3.
4.
5.
6.
Resistant organism
Poor compliance with medication
Alcohol consumption
Smoking
Prior antibiotic use
Underlying condition (FD Vs PUD)
1/8/2014
37
38. Antibiotic resistance
âȘ Resistance to metronidazole is 40% in US and 11%
for clarithromycin
âȘ Resistace to amox and tetracycline is less than 1%
âȘ The resistance to metronidazole is overcome by
increasing doses or combining with bismuth
âȘ Macrolide resistance cant overcome by increasing
dose because these are due to alterations in 23S
ribosomal RNA(A2143G, A2142G & A2142C) which
interferes with ribosomal macrolide binding
1/8/2014
38
40. Side effects of treatment
âȘ Side effects are reported in up to 50 percent of patients taking one
of the triple therapy regimens .
âȘ The adverse effects are usually mild; fewer than 10 percent of
patients stop treatment due to side effects
1. The most common side effect is a metallic taste due
to metronidazole or clarithromycin.
2. Metronidazole can cause a peripheral neuropathy, seizures, and
a disulfiram-like reaction when taken with alcohol.
3. Clarithromycin can cause taste alteration, nausea, vomiting,
abdominal pain, and rarely QT prolongation.
4. Tetracycline can induce a photosensitivity reaction in some
cases. It should also not be administered to pregnant women or
young children.
5. Amoxicillin can cause diarrhea or an allergic reaction with skin
rash.
1/8/2014
40
41. Take home message
1. H. pylori is a common worldwide infection.
2. Established indications for H. pylori cure include
peptic ulcer,(MALT) and uninvestigated
dyspepsia.
3. Non-endoscopic and endoscopic tests are
available toidentify H. pylori.
4. Proton pump inhibitor (PPI), clarithromycin, and
amoxicillin or metronidazole or a
PPI, bismuth, tetracycline,and metronidazole for
10â14 days are accepted first line treatment
1/8/2014
41